Guillain-Barré syndrome: An update

Steve Vucic, Matthew C. Kiernan, David Cornblath

Research output: Contribution to journalArticle

Abstract

Guillain-Barré syndrome (GBS) is an acute polyneuropathy consisting of different subtypes. Acute inflammatory demyelinating polyradiculoneuropathy, the classic demyelinating form of GBS, accounts for 90% of all GBS cases in the Western world. Acute motor axonal neuropathy (AMAN) and acute motor and sensory axonal neuropathy (AMSAN) are axonal forms of GBS that are more prevalent in Asia, South and Central America, often preceded by infection by Campylobacter jejuni. AMAN and AMSAN may be mediated by specific anti-ganglioside antibodies that inhibit transient sodium ion (Na+) channels. The efficacy of plasmapheresis and intravenous immunoglobulin has been established in large international randomised trials, with corticosteroids proven ineffective. Although axonal demyelination is an established pathophysiological process in GBS, the rapid improvement of clinical deficits with treatment is consistent with Na+ channel blockade by antibodies or other circulating factors, such as cytokines. This review provides an update on the epidemiology, clinical features, diagnosis, pathogenesis and treatment of GBS.

Original languageEnglish (US)
Pages (from-to)733-741
Number of pages9
JournalJournal of Clinical Neuroscience
Volume16
Issue number6
DOIs
StatePublished - Jun 2009

Fingerprint

Central America
Western World
Campylobacter jejuni
Guillain-Barre Syndrome
Plasmapheresis
Polyneuropathies
South America
Sodium Channels
Gangliosides
Intravenous Immunoglobulins
Demyelinating Diseases
Anti-Idiotypic Antibodies
Adrenal Cortex Hormones
Epidemiology
Cytokines
Antibodies
Therapeutics
Infection

Keywords

  • Acute inflammatory demyelinating polyradiculoneuropathy
  • Acute motor and sensory axonal neuropathy
  • Acute motor axonal neuropathy
  • Guillain-Barré syndrome

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Physiology (medical)

Cite this

Guillain-Barré syndrome : An update. / Vucic, Steve; Kiernan, Matthew C.; Cornblath, David.

In: Journal of Clinical Neuroscience, Vol. 16, No. 6, 06.2009, p. 733-741.

Research output: Contribution to journalArticle

Vucic, Steve ; Kiernan, Matthew C. ; Cornblath, David. / Guillain-Barré syndrome : An update. In: Journal of Clinical Neuroscience. 2009 ; Vol. 16, No. 6. pp. 733-741.
@article{2ddca16668ed4b919472be03fd239703,
title = "Guillain-Barr{\'e} syndrome: An update",
abstract = "Guillain-Barr{\'e} syndrome (GBS) is an acute polyneuropathy consisting of different subtypes. Acute inflammatory demyelinating polyradiculoneuropathy, the classic demyelinating form of GBS, accounts for 90{\%} of all GBS cases in the Western world. Acute motor axonal neuropathy (AMAN) and acute motor and sensory axonal neuropathy (AMSAN) are axonal forms of GBS that are more prevalent in Asia, South and Central America, often preceded by infection by Campylobacter jejuni. AMAN and AMSAN may be mediated by specific anti-ganglioside antibodies that inhibit transient sodium ion (Na+) channels. The efficacy of plasmapheresis and intravenous immunoglobulin has been established in large international randomised trials, with corticosteroids proven ineffective. Although axonal demyelination is an established pathophysiological process in GBS, the rapid improvement of clinical deficits with treatment is consistent with Na+ channel blockade by antibodies or other circulating factors, such as cytokines. This review provides an update on the epidemiology, clinical features, diagnosis, pathogenesis and treatment of GBS.",
keywords = "Acute inflammatory demyelinating polyradiculoneuropathy, Acute motor and sensory axonal neuropathy, Acute motor axonal neuropathy, Guillain-Barr{\'e} syndrome",
author = "Steve Vucic and Kiernan, {Matthew C.} and David Cornblath",
year = "2009",
month = "6",
doi = "10.1016/j.jocn.2008.08.033",
language = "English (US)",
volume = "16",
pages = "733--741",
journal = "Journal of Clinical Neuroscience",
issn = "0967-5868",
publisher = "Churchill Livingstone",
number = "6",

}

TY - JOUR

T1 - Guillain-Barré syndrome

T2 - An update

AU - Vucic, Steve

AU - Kiernan, Matthew C.

AU - Cornblath, David

PY - 2009/6

Y1 - 2009/6

N2 - Guillain-Barré syndrome (GBS) is an acute polyneuropathy consisting of different subtypes. Acute inflammatory demyelinating polyradiculoneuropathy, the classic demyelinating form of GBS, accounts for 90% of all GBS cases in the Western world. Acute motor axonal neuropathy (AMAN) and acute motor and sensory axonal neuropathy (AMSAN) are axonal forms of GBS that are more prevalent in Asia, South and Central America, often preceded by infection by Campylobacter jejuni. AMAN and AMSAN may be mediated by specific anti-ganglioside antibodies that inhibit transient sodium ion (Na+) channels. The efficacy of plasmapheresis and intravenous immunoglobulin has been established in large international randomised trials, with corticosteroids proven ineffective. Although axonal demyelination is an established pathophysiological process in GBS, the rapid improvement of clinical deficits with treatment is consistent with Na+ channel blockade by antibodies or other circulating factors, such as cytokines. This review provides an update on the epidemiology, clinical features, diagnosis, pathogenesis and treatment of GBS.

AB - Guillain-Barré syndrome (GBS) is an acute polyneuropathy consisting of different subtypes. Acute inflammatory demyelinating polyradiculoneuropathy, the classic demyelinating form of GBS, accounts for 90% of all GBS cases in the Western world. Acute motor axonal neuropathy (AMAN) and acute motor and sensory axonal neuropathy (AMSAN) are axonal forms of GBS that are more prevalent in Asia, South and Central America, often preceded by infection by Campylobacter jejuni. AMAN and AMSAN may be mediated by specific anti-ganglioside antibodies that inhibit transient sodium ion (Na+) channels. The efficacy of plasmapheresis and intravenous immunoglobulin has been established in large international randomised trials, with corticosteroids proven ineffective. Although axonal demyelination is an established pathophysiological process in GBS, the rapid improvement of clinical deficits with treatment is consistent with Na+ channel blockade by antibodies or other circulating factors, such as cytokines. This review provides an update on the epidemiology, clinical features, diagnosis, pathogenesis and treatment of GBS.

KW - Acute inflammatory demyelinating polyradiculoneuropathy

KW - Acute motor and sensory axonal neuropathy

KW - Acute motor axonal neuropathy

KW - Guillain-Barré syndrome

UR - http://www.scopus.com/inward/record.url?scp=67349199109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349199109&partnerID=8YFLogxK

U2 - 10.1016/j.jocn.2008.08.033

DO - 10.1016/j.jocn.2008.08.033

M3 - Article

C2 - 19356935

AN - SCOPUS:67349199109

VL - 16

SP - 733

EP - 741

JO - Journal of Clinical Neuroscience

JF - Journal of Clinical Neuroscience

SN - 0967-5868

IS - 6

ER -